Organization | Insmed, Inc.

Insmed, Inc. Report issue

For profit Phase 2 Phase 3

Founded: Bridgewater Township NJ United States (1988)

Status: Acquired by Merck (2009)

Organization Overview

First Clinical Trial

2005

NCT00102531

First Marketed Drug

2005

mecasermin (increlex)

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Imsmed Incorporated | INSMED | INSMED INC | Insmed Incorporated

Active Ingredients

Marketed Drugs (2)

amikacin (Amikin) (2018)

mecasermin (increlex) (2005)

Drugs in Phase 3 Trials (6)

amikacin (Amikin) (10 trials)

azd7986 (6 trials)

azithromycin (zithromax) (2 trials)

ethambutol (myambutol) (2 trials)

mecasermin (increlex) (4 trials)

tobramycin (nebcin) (1 trial)

Drugs in Phase 2 Trials (6)

Key: Insmed, Inc. (5) Acquired (1)

aminoglycoside (1 trial)

cisplatin (platinol) (1 trial)

ins1007 (1 trial)

insulin-like growth factor-binding protein-3 (1 trial)

masoprocol (actinex) (1 trial)

treprostinil (remodulin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bronchiectasis (Phase 3)

Communicable Diseases (Phase 3)

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Infections (Phase 3)

Laron Syndrome (Phase 3)

Lung Diseases (Phase 2)

Mycobacterium Infections (Phase 3)

Mycobacterium Infections, Nontuberculous (Phase 3)

Myotonic Dystrophy (Phase 2)

Noonan Syndrome (Phase 2)

Osteosarcoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Pseudomonas Infections (Phase 3)

Respiratory Aspiration (Phase 2)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 28
# of Trial APIs: 12